– Company ended the quarter with $58.2 million in cash
– Driving continued progress across diversified pre-clinical and clinical development pipeline
Read more at globenewswire.comAll information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
– Company ended the quarter with $58.2 million in cash
– Driving continued progress across diversified pre-clinical and clinical development pipeline
Read more at globenewswire.com